Johnson & Johnson [NYSE: JNJ] traded at a low on 07/12/22, posting a -1.40 loss after which it closed the day’ session at $175.85. The company report on June 20, 2022 that Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
The new Satellite Center will work to accelerate discovery research against flaviviruses, including dengue, which impacts 400 million people each year.
This effort will build on Johnson & Johnson’s decade-long legacy and ongoing collaboration with Duke-NUS in early-stage dengue research.
The results of the trading session contributed to over 4684825 shares changing hands. Over the past one week, the price volatility of Johnson & Johnson stands at 1.20% while the volatility over the past one month is 1.81%.
The market cap for JNJ stock reached $463.30 billion, with 2.63 billion shares outstanding and 2.63 billion shares in the current float. Compared to the average trading volume of 7.44M shares, JNJ reached a trading volume of 4684825 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Johnson & Johnson [JNJ]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $189.72 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Daiwa Securities have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 22, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on May 23, 2022, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $173, while Morgan Stanley analysts kept a Equal-Weight rating on JNJ stock. On March 16, 2022, analysts increased their price target for JNJ shares from 180 to 183.
The Average True Range (ATR) for Johnson & Johnson is set at 3.11, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 4.88. The Price to Book ratio for the last quarter was 6.19, with the Price to Cash per share for the same quarter was set at 11.53. Price to Free Cash Flow for JNJ in the course of the last twelve months was 54.04 with Quick ratio for the last quarter at 1.10.
How has JNJ stock performed recently?
Johnson & Johnson [JNJ] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.29. With this latest performance, JNJ shares gained by 1.23% in over the last four-week period, additionally plugging by 1.09% over the last 6 months – not to mention a rise of 3.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 46.71, with the RSI for the last a single of trading hit 43.20, and the three-weeks RSI is set at 47.99 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 176.98, while it was recorded at 177.86 for the last single week of trading, and 170.68 for the last 200 days.
Johnson & Johnson [JNJ]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +26.11 and a Gross Margin at +68.14. Johnson & Johnson’s Net Margin is presently recorded at +22.27.
Return on Equity for this stock inclined to 30.41, with Return on Assets sitting at 11.70.
Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
Earnings analysis for Johnson & Johnson [JNJ]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 4.63%.
Insider trade positions for Johnson & Johnson [JNJ]
There are presently around $324,477 million, or 70.30% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 238,141,110, which is approximately 1.43% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 200,799,189 shares of the stock with an approximate value of $35.81 billion in JNJ stocks shares; and STATE STREET CORP, currently with $25.37 billion in JNJ stock with ownership of nearly -1.694% of the company’s market capitalization.
Positions in Johnson & Johnson stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,813 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 64,156,007 shares. Additionally, 1,547 investors decreased positions by around 62,750,609 shares, while 367 investors held positions by with 1,692,422,258 shares. The mentioned changes placed institutional holdings at 1,819,328,874 shares, according to the latest SEC report filing. JNJ stock had 147 new institutional investments in for a total of 3,951,872 shares, while 90 institutional investors sold positions of 1,650,176 shares during the same period.